128 related articles for article (PubMed ID: 1486193)
1. New trends in non-absorbable antibiotics in gastrointestinal disease.
Di Febo G; Calabrese C; Matassoni F
Ital J Gastroenterol; 1992; 24(9 Suppl 2):10-3. PubMed ID: 1486193
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections.
Gerard L; Garey KW; DuPont HL
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):201-11. PubMed ID: 15918778
[TBL] [Abstract][Full Text] [Related]
3. Non-absorbable antibiotics and small bowel bacterial overgrowth.
Corazza GR; Sorge M; Strocchi A; Benati G; Di Sario A; Treggiari EA; Brusco G; Gasbarrini G
Ital J Gastroenterol; 1992; 24(9 Suppl 2):4-9. PubMed ID: 1486197
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin pharmacology and clinical implications.
Ojetti V; Lauritano EC; Barbaro F; Migneco A; Ainora ME; Fontana L; Gabrielli M; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):675-82. PubMed ID: 19442033
[TBL] [Abstract][Full Text] [Related]
6. Biologic properties and clinical uses of rifaximin.
DuPont HL
Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
[TBL] [Abstract][Full Text] [Related]
7. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.
Scarpignato C; Pelosini I
Digestion; 2006; 73 Suppl 1():13-27. PubMed ID: 16498249
[TBL] [Abstract][Full Text] [Related]
8. Non-absorbable antibiotics in the treatment of diverticular disease of the colon.
Papi C; Camarri E
Ital J Gastroenterol; 1992; 24(9 Suppl 2):19-22. PubMed ID: 1336684
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
10. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.
Lauritano EC; Gabrielli M; Lupascu A; Santoliquido A; Nucera G; Scarpellini E; Vincenti F; Cammarota G; Flore R; Pola P; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2005 Jul; 22(1):31-5. PubMed ID: 15963077
[TBL] [Abstract][Full Text] [Related]
12. [Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology].
Rabenstein T; Fromm MF; Zolk O
Z Gastroenterol; 2011 Feb; 49(2):211-24. PubMed ID: 21225568
[TBL] [Abstract][Full Text] [Related]
13. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.
Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M
Eur Rev Med Pharmacol Sci; 1999; 3(1):27-30. PubMed ID: 10710827
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin: a nonabsorbed oral antibiotic.
Baker DE
Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929
[TBL] [Abstract][Full Text] [Related]
15. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin.
Di Stefano M; Corazza GR
Chemotherapy; 2005; 51 Suppl 1():103-9. PubMed ID: 15855754
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
Adachi JA; DuPont HL
Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial drugs in Crohn's disease.
Pallone F; Boirivant M; Fais S; Luzza F; Doldo P; Monteleone G; Aloi A
Ital J Gastroenterol; 1992; 24(9 Suppl 2):17-8. PubMed ID: 1486195
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
Gasztonyi B; Hunyady B
Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin: beyond the traditional antibiotic activity.
Calanni F; Renzulli C; Barbanti M; Viscomi GC
J Antibiot (Tokyo); 2014 Sep; 67(9):667-70. PubMed ID: 25095806
[TBL] [Abstract][Full Text] [Related]
20. Management of inflammatory bowel disease: does rifaximin offer any promise?
Gionchetti P; Rizzello F; Morselli C; Romagnoli R; Campieri M
Chemotherapy; 2005; 51 Suppl 1():96-102. PubMed ID: 15855753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
